CL2013002836A1 - Composición farmaceutica que comprende una mezcla de antígeno en particular que tiene uno o mas epítopos de las proteinas del virus de la inmunodeficiencia humana (hiv) gal y/o pol y una bacteria no patógena. - Google Patents

Composición farmaceutica que comprende una mezcla de antígeno en particular que tiene uno o mas epítopos de las proteinas del virus de la inmunodeficiencia humana (hiv) gal y/o pol y una bacteria no patógena.

Info

Publication number
CL2013002836A1
CL2013002836A1 CL2013002836A CL2013002836A CL2013002836A1 CL 2013002836 A1 CL2013002836 A1 CL 2013002836A1 CL 2013002836 A CL2013002836 A CL 2013002836A CL 2013002836 A CL2013002836 A CL 2013002836A CL 2013002836 A1 CL2013002836 A1 CL 2013002836A1
Authority
CL
Chile
Prior art keywords
gal
epitopes
hiv
pharmaceutical composition
immunodeficiency virus
Prior art date
Application number
CL2013002836A
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Lu
Original Assignee
Univ Paris Descartes
Institut De Rech Puor Le Developpement Ird
Biovaxim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46969619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002836(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Paris Descartes, Institut De Rech Puor Le Developpement Ird, Biovaxim Ltd filed Critical Univ Paris Descartes
Publication of CL2013002836A1 publication Critical patent/CL2013002836A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
CL2013002836A 2011-04-06 2013-10-02 Composición farmaceutica que comprende una mezcla de antígeno en particular que tiene uno o mas epítopos de las proteinas del virus de la inmunodeficiencia humana (hiv) gal y/o pol y una bacteria no patógena. CL2013002836A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/072481 2011-04-06
US201161534088P 2011-09-13 2011-09-13
CNPCT/CN2012/070761 2012-01-30
US201261609051P 2012-03-09 2012-03-09

Publications (1)

Publication Number Publication Date
CL2013002836A1 true CL2013002836A1 (es) 2014-07-25

Family

ID=46969619

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002836A CL2013002836A1 (es) 2011-04-06 2013-10-02 Composición farmaceutica que comprende una mezcla de antígeno en particular que tiene uno o mas epítopos de las proteinas del virus de la inmunodeficiencia humana (hiv) gal y/o pol y una bacteria no patógena.

Country Status (19)

Country Link
US (1) US9839684B2 (es)
EP (3) EP3173096A1 (es)
JP (1) JP6054370B2 (es)
KR (1) KR101814857B1 (es)
CN (1) CN105709221B (es)
AP (1) AP2013007166A0 (es)
AU (1) AU2012238351B2 (es)
BR (1) BR112013025481B8 (es)
CA (1) CA2832022C (es)
CL (1) CL2013002836A1 (es)
DK (1) DK2694101T3 (es)
ES (1) ES2606511T3 (es)
IL (1) IL228666A (es)
MX (1) MX343037B (es)
PL (1) PL2694101T3 (es)
PT (1) PT2694101T (es)
RU (1) RU2609769C2 (es)
SG (1) SG194079A1 (es)
WO (1) WO2012137071A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1397155E (pt) * 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
SG11201706132YA (en) * 2015-01-30 2017-09-28 Univ Tokyo Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent
CN114025792A (zh) * 2019-03-21 2022-02-08 21C生物公司 针对感染期间的致病性免疫激活细胞的疫苗
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
JP7339450B2 (ja) 2020-01-10 2023-09-05 イミュノバイオーム インコーポレイテッド 新規なラクトバシラスプランタルム菌株、菌株由来多糖体及びその用途
JP2024507000A (ja) * 2021-02-02 2024-02-15 プロバクサス，インコーポレイティド 新規免疫調節プラットフォーム及び利用方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243029A1 (en) 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene
JPS6485072A (en) 1987-09-25 1989-03-30 Nat Inst Health Recombinant vaccinia virus
JPH01148183A (ja) 1987-12-04 1989-06-09 Hiroshi Shibuta 組み換えワクチニアウイルス
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
CA2068713A1 (en) 1989-11-20 1991-05-21 Omar K. Haffar Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
EP0449116B2 (en) 1990-03-21 2004-08-25 Geneart GmbH DNA sequences encoding modified retroviral gag polypeptides and vaccines containing them or aggregates thereof
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
ATE241696T1 (de) 1991-06-14 2003-06-15 Virogenetics Corp Rekombinanter hiv-spezifischer impfstoff aus poxviru
EP0538496B1 (en) 1991-08-26 2003-10-29 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
DE4141741A1 (de) 1991-12-13 1993-06-17 Gisela Kielmann Verfahren zur bekaempfung des human imune deficiency virus
US6511845B1 (en) 1992-08-07 2003-01-28 Alan R. Davis Methods for producing an immune response against HIV-1
US6136318A (en) 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
JPH07170982A (ja) 1993-09-09 1995-07-11 Nisshin Oil Mills Ltd:The ワクチンおよびその製造方法
WO1995007099A1 (fr) 1993-09-09 1995-03-16 The Nisshin Oil Mills, Ltd. Vaccin et procede pour sa production
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
WO1996011708A1 (en) 1994-10-18 1996-04-25 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
WO1996040880A1 (en) 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
JPH1085072A (ja) 1996-09-13 1998-04-07 Kichinosuke Takemaru 家具転倒防止器具
US6001155A (en) 1997-03-17 1999-12-14 Pease; John R. Polyphasic pressurized homogenizer
HRP980143A2 (en) * 1997-04-09 1999-02-28 Soo Sung Ko 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
US5895758A (en) * 1997-06-10 1999-04-20 Bio-Energy Systems Strain of lactobacillus Plantarum
US6261568B1 (en) 1997-06-11 2001-07-17 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
JP3899165B2 (ja) 1997-08-06 2007-03-28 ビー・エル・オートテック株式会社 ロボットアームの過負荷保護装置
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6121021A (en) 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
US7189402B1 (en) 1998-02-06 2007-03-13 Research Development Foundation Live vaccine for human immunodeficiency virus
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
EP1084709A1 (en) 1999-09-17 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Oral recombinant lactobacilli vaccines
EP1226263A1 (en) 1999-10-26 2002-07-31 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US20040101957A1 (en) 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
WO2002031168A2 (en) 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
GB0030857D0 (en) 2000-12-18 2001-01-31 Medical Res Council Therapeutic compositions
KR20020059856A (ko) 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
CA2454959C (en) 2001-03-08 2018-07-10 Bernard Moss Mva expressing modified hiv envelope, gag, and pol genes
WO2002102409A1 (en) 2001-06-19 2002-12-27 Medical Research Council Inactivated mycobacterial ompatb and uses thereof
AU2002332736A1 (en) 2001-08-30 2003-03-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of New adenovirus type 7 vectors
US20070077257A1 (en) 2001-09-14 2007-04-05 Emini Emilio A Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
EP1467771B1 (en) 2001-11-14 2008-04-16 Novavax, Inc. Mycobacterial vaccine
WO2003050238A2 (en) 2001-12-11 2003-06-19 University Of Iowa Research Foundation Receptor-targeted adenoviral vectors
US20040009937A1 (en) 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
CN1646020A (zh) 2002-01-31 2005-07-27 圣必健公司 将核酸和/或蛋白质导入呼吸系统的方法与制剂
JP4343708B2 (ja) 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
JP2003321391A (ja) 2002-04-30 2003-11-11 Japan Science & Technology Corp 組換えワクシニアウイルスを用いたｈｉｖワクチン
DE10221411B4 (de) 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
JP2005527235A (ja) * 2002-05-31 2005-09-15 シファーゲン バイオシステムズ， インコーポレイテッド デフェンシン：抗ウイルス剤の使用
CN1490056A (zh) 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
EP2359851A3 (en) 2003-03-28 2011-08-31 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
JP2007518460A (ja) 2003-05-09 2007-07-12 イントラヴァック インコーポレーテッド 皮内、皮下及び筋肉内注射用の無針注射器及びアンプル
WO2005017208A1 (en) 2003-07-31 2005-02-24 George Mason Intellectual Properties, Inc. Compositions and methods for treating or preventing hiv infection
MXPA06001996A (es) * 2003-08-28 2006-06-20 Immune Response Corp Inc Composiciones de hiv inmunogeneticas y metodos relacionados.
JP2007037402A (ja) 2003-11-28 2007-02-15 Primmune:Kk 抗ヒト免疫不全ウイルス感染防御用キメラ５型／３５型アデノウイルスベクター
WO2005111205A1 (en) 2004-05-18 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US8541167B2 (en) * 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
US7488828B2 (en) 2004-06-25 2009-02-10 Dow Agrosciences Llc Process for the preparation of 4-trifluoromethyl-2(1H)-pyridinone
AU2005279799A1 (en) 2004-08-27 2006-03-09 Emory University Recombinant MVA viruses expressing Clade A/G, Clade B and Clade C modified HIV ENV, GAG and POL genes
US20060093623A1 (en) * 2004-10-04 2006-05-04 Biovaxim Limited, A Corporation Of United Kingdom Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection
CA2853335A1 (en) * 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
MX2007014038A (es) 2005-05-12 2008-02-11 Glaxo Group Ltd Composicion de vacuna.
EP1723965A1 (en) 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
CA2654457A1 (en) 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof
ES2531018T3 (es) 2007-04-12 2015-03-09 Mico Bio Inc Vacuna contra la tuberculosis y método de uso de la misma
WO2009093900A1 (en) 2008-01-25 2009-07-30 Stichting Top Institute Food And Nutrition Mid-log phase lactic acid bacteria for inducing immune tolerance in a subject

Also Published As

Publication number Publication date
AP2013007166A0 (en) 2013-10-31
JP2014511856A (ja) 2014-05-19
IL228666A (en) 2017-12-31
DK2694101T3 (en) 2017-01-09
IL228666A0 (en) 2013-12-31
EP2694101B1 (en) 2016-09-14
RU2013147745A (ru) 2015-05-20
EP3173096A1 (en) 2017-05-31
RU2609769C2 (ru) 2017-02-02
WO2012137071A2 (en) 2012-10-11
KR20140042800A (ko) 2014-04-07
SG194079A1 (en) 2013-11-29
ES2606511T3 (es) 2017-03-24
MX343037B (es) 2016-10-20
CA2832022A1 (en) 2012-11-10
CN105709221B (zh) 2020-11-17
JP6054370B2 (ja) 2016-12-27
US9839684B2 (en) 2017-12-12
BR112013025481A2 (pt) 2018-12-11
PL2694101T3 (pl) 2017-07-31
EP3000476A1 (en) 2016-03-30
CN105709221A (zh) 2016-06-29
US20140302089A1 (en) 2014-10-09
BR112013025481B8 (pt) 2022-11-22
MX2013011540A (es) 2014-04-16
KR101814857B1 (ko) 2018-01-04
EP2694101A2 (en) 2014-02-12
AU2012238351B2 (en) 2016-11-24
NZ616283A (en) 2014-10-31
PT2694101T (pt) 2016-12-19
BR112013025481B1 (pt) 2020-06-23
WO2012137071A3 (en) 2012-11-29
AU2012238351A1 (en) 2013-10-24
CA2832022C (en) 2019-01-08

Similar Documents

Publication Publication Date Title
CL2013002836A1 (es) Composición farmaceutica que comprende una mezcla de antígeno en particular que tiene uno o mas epítopos de las proteinas del virus de la inmunodeficiencia humana (hiv) gal y/o pol y una bacteria no patógena.
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
CY1121712T1 (el) Γελη λυματος αιμοπεταλιων
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
UY35416A (es) Anticuerpos humanos de la proteína f del virus respiratorio sincicial y métodos de uso de estos.
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
EP3505620A4 (en) 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
EP4233903A3 (en) Compositions and methods for the treatment of immunodeficiency
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2015016627A (es) Vacuna para la malaria.
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EA201290956A1 (ru) Вакцина против вич
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
AR101814A1 (es) Partícula de tipo virus flavivirus
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
WO2016100615A3 (en) Methods and composition for neutralization of influenza
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico